Publications Repository - Helmholtz-Zentrum Dresden-Rossendorf

2 Publications
Perfluorinated Calixarene Shuttles for Radium and Barium
Reissig, F.; Bauer, D.; Pietzsch, H.-J.; Steinbach, J.; Mamat, C.ORC
Alpha therapy is continually discussed in radiopharmaceutical research. [223Ra]RaCl2 is the only EMA- and FDA-approved alpha-emitting radiopharmaceutical so far. Since the use of 223Ra is only based on its calcimimetic behavior. It is directly bond to bone structures in the body. To enhance the therapeutic potential of radium isotopes, it is necessary to develop novel carrier systems for radium ions as a base of biological targeting units. By the combination of 223Ra or 224Ra, which both have suitable physical half-lives for therapeutic applications, and 131Ba which has a similar half-life but diagnostic radiation properties, a theragnostic idea can also be followed. Our project aims at the synthesis of calixarene-based ligands for the stable complexation of barium and radium ions. Recent studies in our group have already shown the high potential of such ligands.
Keywords: Radium-223, Barium-131, Calixarene
  • Poster
    23rd International Symposium on Radiopharmaceutical Sciences (ISRS 2019), 26.-31.05.2019, Peking, China
  • Open Access LogoAbstract in refereed journal
    Journal of Labelled Compounds and Radiopharmaceuticals 62(2019), S261

Publ.-Id: 29045 - Permalink